OBJECTIVES

: To determine the advisability of setting up Risk Sharing Agreements (RSA) in the Algerian hospital market in order to improve patient access to innovative medicines

METHODS

: Analysis of expenditure on drugs of the Central Hospitals Pharmacy (PCH) on the years 2016, 2017 and 2018, according to the therapeutic classes with a projection on the three years to come, an analysis of the times of access to the market of therapeutic innovations in Algeria, and conduct a simulation of the profits to be made thanks to RSA;

RESULTS

: PCH spending over the last three years on drugs shows that the Oncology class consumes nearly 400 million USD or more than 40% of the global budget intended for pharmaceutical products, this spending will increase to 470 M USD in 2022 according to the projection of the PCH, the hematology class for its part represents more than 150 M USD, which is about 20% of the global budget, with a projection on 2022 of more than 200 M USD, The analysis of the times of access to the market of therapeutic innovations show that it is getting slower and slower, the results of our study show that this is mainly due to the need for health authorities to control spending on drugs; an analysis of the financial impact generated by risk-sharing contracts in France and Canada has shown that the sums recovered by payers represent rates of 0.1% and 0.2% of health expenditure respectively.

CONCLUSIONS

: The efforts made by the Algerian health authorities in terms of cost control are not sufficient, moreover, patients' access to therapeutic innovations is greatly affected, an extrapolation on the savings that can be made while allowing better access to therapeutic innovation shows that the RSA could constitute a rational and just solution, remains to put the regulatory framework to implement them.